Hong Kong, China, May 25, 2026
Cornerstone Robotics (CSR) has announced that its Sentire® Endoscopic Surgical System has officially received both European Union CE Mark certification under the Medical Device Regulation (MDR) and Singapore Health Sciences Authority (HSA) certification, marking a major milestone in the company’s global expansion strategy for advanced robotic-assisted surgery. The dual approvals authorize the Sentire® Surgical System for minimally invasive procedures across general surgery, gynecology, thoracic surgery, and urology, significantly strengthening the company’s presence in both European and Asia-Pacific healthcare markets.
The achievement positions Cornerstone Robotics among the growing number of global innovators competing within the rapidly expanding surgical robotics industry. Company executives stated that the approvals validate the platform’s safety, efficacy, engineering quality, and clinical performance while accelerating commercial deployment opportunities across major international healthcare systems. The certifications also reinforce increasing global demand for next-generation robotic surgery technologies capable of improving surgical precision, workflow integration, and patient outcomes.
Sentire® Surgical System Expands Global Clinical Presence
The Sentire® Surgical System is a high-end robotic-assisted surgical platform designed to integrate advanced engineering, imaging technologies, software systems, and clinical workflows into minimally invasive surgical procedures. Cornerstone Robotics stated that obtaining CE certification confirms the system’s compliance with some of the world’s most stringent medical device regulatory and quality standards.
The company has already established an early clinical presence in the United Kingdom through a partnership with Portsmouth Hospitals University NHS Trust (PHU). Since 2025, the collaboration has supported fully compliant clinical investigations involving the Sentire® Surgical System across multiple specialties including urology, gynecology, and gastrointestinal surgery. According to the company, the system has successfully completed numerous complex procedures during clinical evaluations, while surgeons and clinicians reported strong satisfaction with its performance and patient outcomes.
Advertisement
Cornerstone Robotics emphasized that real-world clinical data generated through these investigations will support evidence-based research, surgical training programs, and broader international adoption strategies. The company believes that surgeon familiarity, operational efficiency, and integrated training support will be critical for accelerating future robotic surgery adoption globally.
Singapore Approval Strengthens Asia-Pacific Expansion
The simultaneous approval from Singapore’s Health Sciences Authority is viewed as especially significant because Singapore is widely recognized as one of the most advanced and rigorous medical device regulatory environments within the Asia-Pacific region. Company executives stated that obtaining both EU MDR and Singapore HSA certifications demonstrates the Sentire® Surgical System’s ability to meet diverse international regulatory standards while supporting broader healthcare market access.
Cornerstone Robotics has continued strengthening its Asia-Pacific collaboration network through partnerships with healthcare and academic institutions across Singapore. The company previously signed a tripartite memorandum of understanding with the National Healthcare Group (NHG) and the Lee Kong Chian School of Medicine at Nanyang Technological University to support healthcare innovation and robotic surgery ecosystem development in Singapore.
In April 2026, the company completed the first installation of the Sentire® Surgical System at Woodlands Hospital under NHG. The deployment supports surgeon training, workflow adaptation assessments, and system evaluations involving multiple healthcare institutions across Singapore. Company leaders believe these initiatives will accelerate adoption of robotic-assisted surgery throughout the broader Asia-Pacific region.
Full-Stack Innovation Supports Long-Term Growth Strategy
Cornerstone Robotics stated that its vertically integrated development model and full-stack in-house research and development capabilities remain central to the company’s competitive advantage. The company believes this high level of technological integration improves supply chain stability, clinical performance, operational efficiency, and long-term innovation potential within the highly competitive surgical robotics market.
The latest regulatory milestones also follow the company’s successful US$200 million oversubscribed financing round completed in November 2025, highlighting growing investor confidence in the company’s long-term commercial prospects and global expansion strategy. Industry analysts believe the combination of international regulatory approvals, real-world clinical validation, and strong financial backing may significantly strengthen Cornerstone Robotics’ position within the global robotic surgery sector.
As demand for minimally invasive surgical technologies continues rising worldwide, experts expect advanced robotic platforms such as Sentire® to play an increasingly important role in improving surgical precision, reducing complications, and enhancing patient recovery outcomes across multiple clinical specialties.
As awareness of migraine disorders continues expanding globally, experts expect CGRP inhibitors to remain one of the most influential therapeutic categories within the future neurological disease treatment landscape.
Source: Cornerstone Robotics press release
